在AFLIBERCEPT与RANIBIZUMAB治疗期间的脏损伤:基于人口的研究
Robert J Campbell1,2,3, Sherif R El-Defrawy4,5, Sudeep S Gill1,6,7
1ICES, Kingston and Toronto, Ontario, Canada.
Retina (Philadelphia, Pa.)
|September 9, 2025
概括
用于治疗眼睛疾病的静脉内阿弗利伯塞普和拉尼比祖马布在老年人中表现出类似的损伤风险. 这一发现对于了解这些血管内皮生长因子抑制剂的安全性至关重要.
科学领域:
- 眼科医生 眼科 眼科
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 系统性血管内皮生长因子 (VEGF) 抑制剂可以导致损伤.
- 静脉内服aflibercept比拉尼比祖马布更能影响系统VEGF水平.
- 了解这些治疗方法的安全概况至关重要.
研究的目的:
- 为了比较患者接受静脉注射aflibercept与拉尼比祖马布的损伤的风险.
- 评估与这些抗VEGF疗法相关的不良结局.
主要方法:
- 基于人口的队列研究在加拿大安大略省.
- 包括44571名66岁以上的患者,他们最近接受了aflibercept或ranibizumab (2015-2019) 的治疗.
- 对基线和时间变化的共变量进行控制,以比较结局.
主要成果:
- 复合结结果发生在12.0%的aflibercept接受者和10.0%的拉尼比祖马布接受者之间.
- 在5年的随访期间,相对风险为1.00 (95% CI:0.93-1.06).
- 在视网膜疾病小组之间没有发现风险的显著差异.
结论:
- 内阿弗利塞普和拉尼比祖马布具有可比的脏不良事件风险.
- 这种相似之处存在,尽管它们的系统性药理动力学存在差异.
- 这两种治疗方法在老年人群中似乎具有相似的安全性.
相关概念视频
Acute Kidney Injury IV: Diagnostic Studies and Prevention
271
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
271
Acute Kidney Injury I: Introduction
586
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
586
Acute Kidney Injury II: Pathophysiology
910
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
910
Acute Kidney Injury III: Clinical Manifestations
828
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
828
Acute Kidney Injury V: Interprofessional Care
297
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
297
Renal Failure: Dose Adjustments
439
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
439


